Postdoctoral Research Fellow/Associate - Department of Medical Physics

LSU Health launches radiation oncology department. KEY TAKEAWAYS: * LSU Health New Orleans is establishing its first academic Department of Radiation Oncology. * Puneeth Iyengar will lead the department after joining LSU Health from Memorial Sloan Kettering Cancer Center. * Iyengar will also practice at University Medical Center New Orleans and oversee a statewide clinical trial network. * The expansion supports the LSU LCMC Health Cancer Center's pursuit of National Cancer Institute designation. LSU Health New Orleans is establishing its first academic Department of Radiation Oncology and has recruited physician-scientist Puneeth Iyengar to lead it, expanding the institution's cancer treatment, research and physician training programs. The department, approved by the LSU Board of Supervisors and Louisiana Board of Regents, will combine patient care, clinical research and medical education while supporting the LSU LCMC Health Cancer Center's effort to earn National Cancer Institute designation. Iyengar joins LSU Health New Orleans from Memorial Sloan Kettering Cancer Center, where he served as director of the Metastatic Service in the Department of Radiation Oncology. His work has focused on lung cancer, metastatic disease, precision radiation therapy and treatments combining radiation with systemic therapies. As chair, Iyengar will recruit faculty, develop clinical trials, expand multidisciplinary cancer programs and oversee education and training for medical students and physicians. "Throughout my career, I have had the privilege of working at institutions committed to advancing cancer care through research, innovation and collaboration," Iyengar said. "What attracted me to LSU Health New Orleans and the LSU LCMC Health Cancer Center was the opportunity to build something with the potential to make a lasting difference." Iyengar was also named associate director for intercampus research for the LSU LCMC Health Cancer Center. In that role, he will oversee development of a statewide digital early-phase clinical trial network designed to connect cancer physicians and patients across Louisiana. He also plans to create a research group involving the LSU LCMC Health Cancer Center, Pennington Biomedical Research Center and LSU Health Shreveport to study the effects of metabolic health and nutrition on cancer care and outcomes. Iyengar will practice at University Medical Center New Orleans, treating patients with lung and other thoracic cancers, metastatic disease and complex cancers requiring specialized radiation treatment. His work will include approaches combining radiation with immunotherapy and other targeted therapies. "Dr. Iyengar brings the experience, vision and scientific leadership needed to build an exceptional department," said David Guzick, senior vice chancellor of LSU Health New Orleans. "His work will help educate tomorrow's physicians, expand access to highly specialized cancer care and reinforce our role as one of Louisiana's leading academic health sciences institutions." Radiation therapy is used in the treatment of more than half of cancer patients, according to LSU Health. The new department will provide an academic structure for expanding research, clinical trials, faculty recruitment and physician education while strengthening collaboration among oncologists, surgeons and scientists. Iyengar serves on the National Cancer Institute's Thoracic Malignancy Steering Committee and is translational vice chair of the NCI NRG Lung Committee. He previously held several leadership positions at UT Southwestern Medical Center and earned his medical and doctoral degrees from Albert Einstein College of Medicine. He completed his radiation oncology residency at the University of Texas MD Anderson Cancer Center.

OnCusp Therapeutics announces positive Phase 1b data evaluating its cdh6-directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) presented at Plenary Oral session of the IGCS 2026 Annual Global Meeting. Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 At the September 23, 2026, data cutoff, CUSP06 achieved a 62% objective response rate (ORR) in patients treated at 4.0mg/kg in Phase 1b with response and durability data continuing to mature Robust activity observed in patients previously treated with mirvetuximab soravtansine, with a 53% ORR CUSP06 demonstrated a manageable safety profile, with primarily hematologic toxicities, no ocular toxicity, and infrequent low-grade pneumonitis (1%) in Ph1b PROC cohorts PRINCETON, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) - OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced initial data from the Company's Phase 1b open-label, multicenter dose-expansion study evaluating its Cadherin-6 (CDH6)-directed antibody-drug conjugate ("ADC"), CUSP06, for the treatment of platinum-resistant ovarian cancer ("PROC"). The Phase 1b data are being presented for the first time by Roisin E. O'Cearbhaill, M.D., Gynecological Medical Oncologist and Cellular Therapist, Memorial Sloan Kettering Cancer Center, at a plenary oral session of the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting, on October 3, 2026, at Palais des Congrès de Montréal in Montréal, Canada. "We are excited to report these initial data from our Phase 1b trial at this year's IGCS Annual Meeting, which reflect the potential of CUSP06 to treat platinum-resistant ovarian cancer in patients who have experienced disease progression after multiple lines of prior therapy," said Dr. Bing Yuan, Co-Founder and CEO of OnCusp Therapeutics. "The 62% ORR observed in the 4.0 mg/kg cohort represents one of the highest response rates reported in PROC patients receiving an experimental TOP1-inhibitor ADC. CUSP06 also demonstrates robust activity in patients previously treated with mirvetuximab soravtansine. Importantly, CUSP06 continues to maintain an acceptable safety and tolerability profile in line with other TOP1 inhibitor ADCs currently in development. We believe these Phase 1b data provide us with strong clinical evidence that CUSP06 is a very active, differentiated and potentially best-in-class CDH6-targeting ADC in ovarian cancer and possibly other CDH6-expressing cancers." "Despite advances in treatment, most patients with ovarian cancer will ultimately develop resistance to platinum-based chemotherapy, highlighting the need for new therapeutic approaches," said Dr. Roisin E. O'Cearbhaill. "The development of highly potent antibody-drug conjugates targeting CDH6, which is frequently overexpressed in ovarian cancer, represents a promising strategy for patients with recurrent and treatment-resistant disease. I am particularly encouraged not only by the response rates observed in this study, but also by the duration of response and the low incidence of pneumonitis, which may suggest a potential safety advantage compared with other TOP1 inhibitor-based ADCs. While these results remain early, the overall findings from this Phase 1b study support the continued development of CUSP06, and I look forward to seeing the program advance into pivotal-stage clinical testing." The Phase 1b trial (NCT06234423) is an open-label multi-center, dose- expansion study evaluating CUSP06 in patients with platinum-refractory/resistant ovarian cancer (PROC), advanced renal cell carcinoma (RCC) and other CDH6-positive solid tumors. More specifically, the Phase 1b portion of the trial included data from 86 heavily pre-treated PROC patients with a median of 3 lines of prior therapy. Eligibility included patients with high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer which is platinum-resistant with 1-4 prior lines of therapy. Four cohorts treated with CUSP06 were evaluated in the Phase 1b trial: 3.6 mg/kg (n=22), 4.0 mg/kg (n=21), 4.0 mg/kg + prophylactic G-CSF (n=20), and 4.4 mg/kg + prophylactic G-CSF (n=23). The primary endpoint of the Phase 1b study was Objective Response Rate (ORR) based on RECIST v1.1, safety parameters (incidence/severity of AEs and SAEs, frequency and duration of dose modifications). Secondary endpoints included Clinical Benefit Rate (CBR), Disease Control Rate (DCR), Duration of Response (DOR), Time to Progression (TTP), Progression Free Survival (PFS) as measured by RECIST v1.1, and Pharmacokinetic (PK) parameters. As of September 23, 2026, there were 81 Ph1B PROC patients evaluable for efficacy in the trial. Summary of efficacy data CUSP06 demonstrated meaningful responses across dose levels in the four patient cohorts, including complete responses (CR): * 50% ORR (10/20) in the 3.6 mg/kg cohort; including 1 CR * 62% ORR (13/21) in the 4.0 mg/kg cohort; including 3 CR * 45% ORR (9/20) in the 4.0 mg/kg + G-CSF cohort * 40% ORR (8/20) in the 4.4 mg/kg + G-CSF cohort; including 1 CR * 53% ORR (16/30) in post-mirvetuximab treated patients; including 1 CR * mDOR from the Phase 1a part of the study HGSOC was 10.5 months, with longest response > 23 months (ongoing) Data from the ongoing Phase 1b study continues to mature, which could provide additional evidence in support of CUSP06 as a potential best-in-class TOP1 ADC therapy for the treatment of PROC. Summary of safety and tolerability data * Most common TRAEs were hematologic (anemia, neutropenia, thrombocytopenia), GI (nausea, vomiting, diarrhea), and fatigue, consistent with TOP1 inhibitor ADC class effects * Dose modifications were primarily driven by hematologic AEs, consistent with mechanism, and were manageable * No ocular toxicity reported * Pneumonitis rate remains rare with only 1 case in 86 patients Presentation Details: Title: Dose-Optimization, Efficacy, and Safety of CUSP06, a Cadherin-6 Directed Antibody-Drug Conjugate, in Platinum-Resistant Ovarian Cancer Session Title: Plenary Oral 2 Abstract Number: 503 CUSP06 has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with platinum-resistant ovarian cancer. About CUSP06 CUSP06 is a Cadherin-6 (CDH6)-targeting antibody-drug conjugate (ADC) now in the Phase 1b portion of a Phase 1 study in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. CUSP06 has shown promising efficacy in heavily pretreated ovarian cancer, with both Phase 1a and Phase 1b results supporting potential best-in-class activity. CUSP06 is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a stable and homogeneous ADC. The payload is a weak substrate for BCRP/P-gp, drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, CUSP06's linker-payload has been shown to have an increased "bystander effect" compared with competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight. OnCusp obtained the exclusive global rights (outside of China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics in 2022. Additional information on the CUSP06-1001 (NCT06234423) trial can be found at ClinicalTrials.gov. About OnCusp Therapeutics OnCusp Therapeutics, Inc., is a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically meaningful outcomes for patients. The company's lead program, CUSP06 - a Cadherin-6 (CDH6)-targeting antibody-drug conjugate (ADC) - is in the final stage of the Phase 1b study in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. OnCusp Therapeutics raised a total of $139M in Seed and Series A fund raising, supported by leading investors such as Novo Holdings, OrbiMed, and F-Prime Capital. OnCusp is headquartered in Princeton, New Jersey. For more information, visit www.oncusptx.com. Anthony H. Kim Chief Financial Officer OnCusp Therapeutics [email protected]

Prime Minister witnesses signing of memorandum of understanding between the Ministry of Public Health and Memorial Sloan Kettering Cancer Center to explore establishing a world-class Cancer Center in Qatar. - Minister of Public Health: Qatar is keen to attract the best specialized international centers to advance cancer patient care and support scientific research and innovation - Establishes a framework for a strategic partnership spanning cancer care, research, artificial intelligence, and innovation - The proposed partnership will bring more than 140 years of clinical excellence, scientific discovery, and innovation to patients in Qatar and the wider region. New York, NY, 23 September 2026 - 4 PM ET - His Excellency Sheikh Mohammed bin Abdulrahman bin Jassim Al Thani, Prime Minister and Minister of Foreign Affairs, today announced the signing of a memorandum of understanding between the Ministry of Public Health and Memorial Sloan Kettering Cancer Center (MSK) - one of the world's leading cancer centers to explore the possibility of developing an integrated cancer center in the State of Qatar, to be operated according to MSK's clinical standards and protocols, positioning it as a regional referral center and destination for patient care. Dr. Selwyn M. Vickers, MSK President and CEO, Scott M. Stuart, Chair of MSK's Board of Trustees, and several other Trustees, were also present at the signing. The memorandum of understanding was signed by His Excellency Mr. Mansoor bin Ebrahim Al Mahmoud, Minister of Public Health, and Dr. Vickers. It establishes a framework to explore the first strategic partnership of its kind in the fields of cancer care, research, artificial intelligence, and innovation. Cancer is a growing public health challenge across the Middle East, with incidence projected to more than double by 2050.[[1]] The memorandum of understanding lays the foundation for the potential development of a comprehensive cancer center in the State of Qatar, operated under MSK's clinical standards and protocols, that would serve as a referral and destination hub for patients across East Africa, Asia, India, and Pakistan, who today have limited access to highly specialized cancer treatment. The proposed partnership also includes a significant investment by the State of Qatar in advancing research, artificial intelligence, and other areas where MSK is known as a world leader. His Excellency Mr. Mansoor bin Ebrahim Al Mahmoud, Minister of Public Health, said: "The signing of this memorandum of understanding allows both sides to explore establishing a distinguished partnership between the Ministry of Public Health and Memorial Sloan Kettering Cancer Center, with the aim of advancing cancer patient care in Qatar and the region, and supporting the development and expansion of scientific research and innovation, in line with the priorities of the National Health Strategy and Qatar National Vision 2030." His Excellency affirmed the State of Qatar's keenness to attract the best specialized international centers to support the country's ongoing efforts to advance cancer patient care, noting the significant progress achieved in treatment, research, and disease prevention, and that the memorandum of understanding supports this progress in delivering the best possible standard of care to patients. Dr. Selwyn M. Vickers, President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center, said: "Cancer remains one of the most significant public health challenges of our time, and the need for specialized care in this field continues to grow. As the world's leading cancer center, we have both the expertise and the responsibility to help. This proposed partnership will bring more than 140 years of clinical excellence, scientific discovery, and innovation to patients in Qatar and the wider region - delivering the same standard of cancer care our center is known for, in fulfillment of our mission to end cancer for life." For his part, Mr. Scott M. Stuart, Chair of the Board of Trustees of Memorial Sloan Kettering Cancer Center, said: "Our Board of Trustees is continuously evaluating global opportunities to advance our mission. This proposed partnership has risen to the level of an institutional priority, given the significant regional need it addresses and its alignment with our center's unique capabilities and expertise. We welcome the State of Qatar's strategic partnership and investment, which will help advance our center's broader mission in research, clinical care, and education, and extend our exceptional expertise and cancer care to patients around the world." The memorandum of understanding also establishes a framework for potential collaboration in precision medicine, cancer research, and innovation - including genomics, cell therapies, cancer vaccines, antibody-based platforms, and clinical trials - in addition to deploying advanced cloud computing and artificial intelligence capabilities to support clinical care, scientific research, diagnostics, drug discovery, and innovation in oncology. Together, these efforts will help translate the latest scientific and clinical developments at Memorial Sloan Kettering Cancer Center into better treatment options and outcomes for patients receiving care at the hospital in Doha. This proposed strategic partnership contributes to strengthening the State of Qatar's leading position in cancer patient care, research, and innovation at both the regional and international levels. About the Ministry of Public Health (MOPH), State of Qatar The Ministry of Public Health (MOPH) is the government authority responsible for setting national health policy and strategy in the State of Qatar. MOPH oversees the country's healthcare system, including primary, secondary, and tertiary care, and works in partnership with Hamad Medical Corporation, the Primary Health Care Corporation, and the private sector to deliver high-quality, accessible healthcare services. The Ministry's mandate includes public health protection, disease prevention, health emergency preparedness, licensing and regulation of healthcare professionals and facilities, food safety, and health financing, guided by the National Health Strategy and aligned with Qatar National Vision 2030. About Memorial Sloan Kettering Cancer Center (MSK) The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world's most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years and ranked as the best hospital in the world for oncology according to Newsweek's World's Best Specialized Hospitals 2027 list. www.mskcc.org. Ministry of Public Health - State of Qatar: [email protected] Memorial Sloan Kettering Cancer Center: [email protected] [1] Znaor, A., Fouad, H., Zahwe, M., Eser, S., Fadhil, I., Soerjomataram, I., Hammerich, A., & Bray, F. (2025). Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer-WHO Regional Office for the Eastern Mediterranean collaboration. The Lancet Oncology, 26(3), e131-e139. https://doi.org/10.1016/S1470-2045(24)00624-7 Media contact. Type of article. Section.